Evidence map›Paper›PMID 34301816›Full record

ArticleJournal for immunotherapy of cancer2021

Predictive value of 3'-deoxy-3'-

Masayuki Sato, Yukihiro Umeda, Tetsuya Tsujikawa, Tetsuya Mori, Miwa Morikawa, Masaki Anzai, Yuko Waseda, Maiko Kadowaki, Yasushi Kiyono, Hidehiko Okazawa and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. 3'-deoxy-3'-EJNMMI research · 2025
    Article
  2. Non-[Pharmaceuticals (Basel, Switzerland) · 2024
    Review
  3. SyntheticRSC medicinal chemistry · 2024
    Review
  4. Molecular imaging to support cancer immunotherapy.Journal for immunotherapy of cancer · 2022
    Review
  5. ComprehensiveFrontiers in immunology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Masayuki SatoThird Department of Internal Medicine, University of Fukui, Eiheiji, Fukui, Japan.ORCID 0000-0002-0213-3187
Yukihiro UmedaThird Department of Internal Medicine, University of Fukui, Eiheiji, Fukui, Japan umeda@u-fukui.ac.jp.ORCID 0000-0002-9826-6856
Tetsuya TsujikawaBiomedical Imaging Research Center, University of Fukui, Eiheiji, Fukui, Japan.
Tetsuya MoriBiomedical Imaging Research Center, University of Fukui, Eiheiji, Fukui, Japan.
Miwa MorikawaThird Department of Internal Medicine, University of Fukui, Eiheiji, Fukui, Japan.
Masaki AnzaiThird Department of Internal Medicine, University of Fukui, Eiheiji, Fukui, Japan.
Yuko WasedaThird Department of Internal Medicine, University of Fukui, Eiheiji, Fukui, Japan.
Maiko KadowakiThird Department of Internal Medicine, University of Fukui, Eiheiji, Fukui, Japan.
Yasushi KiyonoBiomedical Imaging Research Center, University of Fukui, Eiheiji, Fukui, Japan.
Hidehiko OkazawaBiomedical Imaging Research Center, University of Fukui, Eiheiji, Fukui, Japan.ORCID 0000-0001-7046-3383
Tamotsu IshizukaThird Department of Internal Medicine, University of Fukui, Eiheiji, Fukui, Japan.
University of Fukui · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnti-programmed death-1 (anti-PD-1) therapy has shown clinical success in patients with advanced non-small cell lung cancer (NSCLC). However, it is difficult to evaluate the early response to anti-PD-1 therapy. We determined whether changes in 3'-deoxy-3'-[

methodsTwenty-six patients with advanced NSCLC treated with anti-PD-1 antibody were enrolled prospectively and underwent

resultsThe disease control rate was 64%. Patients with non-progressive disease (non-PD) had significantly decreased TLP at 2 weeks, and decreased SUV

conclusionsChanges in TRIAL REGISTRATION NUMBER: jRCTs051180147.

Indexed as

AgedAged, 80 and overCarcinoma, Non-Small-Cell LungFemaleFluorine RadioisotopesHumansImmunotherapyLung NeoplasmsMaleMiddle AgedPositron-Emission TomographyProgrammed Cell Death 1 ReceptorProspective StudiesTreatment OutcomeFluorine RadioisotopesProgrammed Cell Death 1 Receptorimmunotherapylung neoplasmstumor biomarkers

Identifiers

PMID34301816
PMCPMC8296775
OpenAlexW3183740090

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.